Participant flow

Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT · Source last updated 2026-04-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Phase I - Thalidomide Dose Level 600 mg

   id

   FG000

   title

   Phase I - Thalidomide Dose Level 600 mg

2. description

   Phase I - Thalidomide Dose Level 800 mg

   id

   FG001

   title

   Phase I - Thalidomide Dose Level 800 mg

3. description

   Phase I - Thalidomide Dose Level 1000 mg

   id

   FG002

   title

   Phase I - Thalidomide Dose Level 1000 mg

4. description

   Phase 2 Thalidomide Dose Level 1000 mg

   id

   FG003

   title

   Phase 2

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         3

      3. group Id

         FG002

         num Subjects

         3

      4. group Id

         FG003

         num Subjects

         20

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         3

      3. group Id

         FG002

         num Subjects

         3

      4. group Id

         FG003

         num Subjects

         20

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice